[Interstitial pneumonia treated with intermittent cyclophosphamide pulse therapy]. 1996

T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

A 52-year-old woman was admitted to the hospital because of polyarthralgia and dry coughing. A chest X-ray film showed bilateral diffuse reticulo-nodular shadows. A specimen obtained by transbronchial lung biopsy revealed alveolar septal thickening and infiltration by mononuclear cells. Interstitial pneumonia associated with rheumatoid arthritis was diagnosed. Interstitial pneumonia relapsed soon after the first pulse of corticosteroid therapy. Cyclophosphamide pulse therapy was given in addition to a second pulse of corticosteroid therapy; 700 mg of cyclophosphamide (500 mg/m2) was administered intravenously every month and the dose of steroids was gradually reduced. Cyclophosphamide pulse therapy was repeated three times and the dose of oral corticosteroids was reduced from 60 mg to 35 mg. There was no bone marrow suppression or hemorrhagic cystitis after the cyclophosphamide pulses. Eventually, corticosteroid therapy was stopped with no clinical deterioration. This case suggests that intermittent cyclophosphamide pulse therapy can be effective for treatment of interstitial pneumonia unresponsive to corticosteroids.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial

Related Publications

T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
July 1998, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
August 1999, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
June 2005, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
December 1998, European journal of dermatology : EJD,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
July 1997, Internal medicine (Tokyo, Japan),
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
January 2007, Modern rheumatology,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
January 2000, Scandinavian journal of rheumatology,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
July 2008, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
January 2016, Respiration; international review of thoracic diseases,
T Harada, and K Takayama, and K Kimotsuki, and K Hidaka, and H Miyazaki, and K Kuwano, and N Hara
September 2005, The Journal of rheumatology,
Copied contents to your clipboard!